5 Facts you should know about

CAR-T therapy

Chimeric antigen receptor (CAR) T-cell therapy is a technology that can genetically engineer immune cells T cells for use in immunotherapy

Chimeric antigen receptors are receptor proteins that have been engineered to give T cells the new ability to target a specific protein

The receptors are chimeric because they combine both antigen-binding and T cell activating functions into a single receptor

The CAR T-cell therapies approved by FDA to date target one of two antigens on B cells, CD19 or BCM

All currently available CAR T-cell therapies are allogeneic – and customized for each individual patient

Rare Neurology News